Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02532647 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Remimazolam in ASA III and IV Patients Undergoing Colonoscopy
A Phase 3 study, sponsored by Paion UK.
- Completed
- Registry status
- Phase 3
- Development phase
- 79
- Enrollment target
NCT02532647: Completed Phase 3 study, sponsored by Paion UK.
NCT02532647 is a Phase 3 study that has completed, run by Paion UK. The registered enrollment target is 79 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02532647, a Phase 3 study, has completed, sponsored by Paion UK.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 79 participants
- Enrollment target
Study Summary
A prospective, double-blind, randomized, placebo and active controlled, multi-center, parallel group study comparing remimazolam to placebo, with an additional open-label arm for midazolam, in American Society of Anesthesiologists (ASA) Grade III and IV patients (ASA status evaluated by an anesthesiologist not otherwise involved in the study) undergoing a colonoscopy for diagnostic or therapeutic reasons.
Primary Outcome
The success of the procedure, as measured by completion of the colonoscopy procedure, AND no requirement for a rescue sedative medication, AND no requirement of more than 5 doses of study medication within any 15 minute window. (For midazolam: 3 doses within any 12 minute window)
Interventions
- DRUG Placebo
- DRUG Midazolam
- DRUG Remimazolam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2015-11 |
| Est. Completion | 2016-12 |
| Phase | Phase 3 |
What the finished NCT02532647 record still lists
NCT02532647 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 79 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02532647 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02532647 about?
NCT02532647 is a clinical study titled "Safety and Efficacy of Remimazolam in ASA III and IV Patients Undergoing Colonoscopy". A prospective, double-blind, randomized, placebo and active controlled, multi-center, parallel group study comparing remimazolam to placebo, with an additional open-label arm for midazolam, in American Society of Anesthesiologists (ASA) Grade III and IV patients (ASA status evaluated by an anesthesi...
What is the current status of trial NCT02532647?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 79 participants. The study started on 2015-11. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02532647?
The interventions under investigation include: Placebo (DRUG), Midazolam (DRUG), Remimazolam (DRUG).
Who is sponsoring clinical trial NCT02532647?
This trial is sponsored by Paion UK, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02532647's enrollment target sits among peer trials
79 1768th of 2000 higher than 232 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05798897 · 79 participants · Phase 1
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
- NCT06042439 · 79 participants · NA
AM vs PM Exercise Training
- NCT06223555 · 79 participants · NA
Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia